Stockscreener 앱 받기
5.03
0.59%
-0.03
시간 외 거래:
5.06
0.03
+0.60%
전일 마감가:
$5.06
열려 있는:
$5.08
하루 거래량:
26,964
Relative Volume:
0.82
시가총액:
$54.52M
수익:
-
순이익/손실:
$-33.82M
주가수익비율:
-0.1897
EPS:
-26.5174
순현금흐름:
$-66.04M
1주 성능:
+1.00%
1개월 성능:
+32.37%
6개월 성능:
-33.82%
1년 성능:
-40.47%
1일 변동 폭
$4.78
$5.10
1주일 범위
$4.59
$5.10
52주 변동 폭
$2.96
$11.45
Elicio Therapeutics Inc Stock (ELTX) Company Profile
명칭
Elicio Therapeutics Inc
전화
(857) 209-0050
주소
451 D STREET, 5TH FLOOR, BOSTON
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Elicio Therapeutics Reports Inducement Grants - EIN News
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted - The Bakersfield Californian
Elicio Therapeutics Announces Three Upcoming Presentations - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - StockTitan
Elicio Therapeutics CFO resigns to pursue new opportunity By Investing.com - Investing.com Australia
Elicio Therapeutics CFO resigns to pursue new opportunity - Investing.com
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024 - InvestorPlace
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - BioSpace
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - StockTitan
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - wallstreet:online
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - GlobeNewswire
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - Yahoo Finance
Elicio Therapeutics’ US$40 Million ATM and US$11.5 Million Public Offering - Global Legal Chronicle
Therapeutic Vaccine Industry to Witness Massive Growth - openPR
ASCO 2024Chris Haqq - pharmaphorum
Ratios in Focus: Analyzing Elicio Therapeutics Inc. (ELTX)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? - MSN
Elicio Therapeutics sets $11.5 million stock offering By Investing.com - Investing.com Australia
Orion Group Holdings inks $30.5M land sale deal By Investing.com - Investing.com
Apple shares target raised, reiterates Outperform on AI potential By Investing.com - Investing.com
Elicio Therapeutics Shares Drop 35% After Public Offering Prices - MarketWatch
Elicio Therapeutics sets $11.5 million stock offering By Investing.com - Investing.com UK
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?Elicio Therapeutics (NASDAQ ... - Benzinga
Elicio Therapeutics Prices of $11.5 Million Underwritten Public Offering - citybiz
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering - GlobeNewswire
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering - StockTitan
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? - InvestorPlace
Elicio Therapeutics launches public offering of stock and warrants By Investing.com - Investing.com Australia
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? - Benzinga
Elicio reports promising early results in cancer vaccine trial By Investing.com - Investing.com Australia
Elicio reports promising early results in cancer vaccine trial By Investing.com - Investing.com
Elicio Therapeutics launches public offering of stock and warrants By Investing.com - Investing.com India
Elicio Therapeutics launches public offering of stock and warrants - Investing.com
Elicio Therapeutics Shares Slip 28% After Public Offering, Drug Data - MarketWatch
Form 424B5 Elicio Therapeutics, - StreetInsider.com
SEC Form 424B5 filed by Elicio Therapeutics Inc. - Quantisnow
Elicio Therapeutics’ Promising Early Results in Cancer Vaccine Trial - TipRanks
Elicio Therapeutics Announces Proposed Public Offering - ForexTV.com
Elicio Therapeutics shares are trading lower after the company announced preliminary disease-free survival analysis ... - Quantisnow
Elicio Therapeutics Announces Proposed Public Offering - GlobeNewswire
Elicio Therapeutics Announces Proposed Public Offering - GlobeNewswire Inc.
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing ... - The Bakersfield Californian
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a ... - GlobeNewswire
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a ... - Yahoo Finance
Elicio Therapeutics Announces Proposed Public Offering - Yahoo Finance
Elicio Therapeutics Inc (ELTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):